
Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica
Summary
Novartis has secured approval from the United States Food and Drug Administration for Cosentyx to treat polymyalgia rheumatica. This regulatory decision expands the approved medical uses for the pharmaceutical product in the American market.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.